Task Force recommends BRCA mutation screening for high-risk women
According to a new guideline being published in Annals of Internal Medicine, the United States Preventive Services Task Force (USPSTF) recommends that primary care providers screen asymptomatic women with a family history of breast, ovarian, tubal, or peritoneal cancers to determine if that family history may be associated with an increased risk for potentially harmful mutations in breast cancer susceptibility genes BRCA1 or BRCA2. Women who screen positive should have genetic counseling and, if indicated after counseling, BRCA testing.
ConclusionsThe mean age of cancer diagnosis and the mean time periods from RRSO to the diagnosis of cancer are similar to those observed by other researchers. The carriers of c.181T > G and c.5266dupCBRCA1 mutation should be the subject further studies in context of breast and peritoneal cancer risk or time of cancer development after RRSO, respectively.
Introduction: Ovarian cancer is usually detected by peritoneal carcinomatosis with ascites.
Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial. Gynecol Oncol. 2019 Jan 09;: Authors: Fabbro M, Moore KN, Dørum A, Tinker AV, Mahner S, Bover I, Banerjee S, Tognon G, Goffin F, Shapira-Frommer R, Wenham RM, Hellman K, Provencher D, Harter P, Vázquez IP, Follana P, Pineda MJ, Mirza MR, Hazard SJ, Matulonis UA Abstract OBJECTIVE: To analyze the safety and efficacy of niraparib in patients aged ≥70 years with recurrent ovarian cancer in the ENGOT-OV16/NOVA trial. ...
Publication date: Available online 28 October 2018Source: Pathology - Research and PracticeAuthor(s): Miguel Barquín, Constanza Maximiano, Clara Pérez-Barrios, Estela Sanchez-Herrero, María Soriano, Marta Colmena, Manuel García-Espantaleón, Eva Tejerina González, Lourdes Gutierrez, Antonio Carlos Sánchez Ruiz, María Torrente, Mariano Provencio, Atocha RomeroAbstractGenetic screening for BRCA mutations should be offered to all women diagnosed with epithelial ovarian, fallopian tube, and/or peritoneal cancers given the implications for treatment options and cancer risk ...
, Torrente M, Provencio M, Romero A Abstract Genetic screening for BRCA mutations should be offered to all women diagnosed with epithelial ovarian, fallopian tube, and/or peritoneal cancers given the implications for treatment options and cancer risk assessments. Yet, while germline breast cancer susceptibility gene 1 (BRCA1) and breast cancer susceptibility gene 2 (BRCA2) testing is commonly performed, BRCA1/2 somatic mutations testing is rather challenging since the poor quality of DNA extracted from formalin fixed paraffin embedded (FFPE) samples can significantly impair this process. Peritoneal lavage is routi...
Condition: HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer Interventions: Drug: PF-06873600; Drug: Endocrine Therapy 1; Drug: Endocrine Therapy 2 Sponsor: Pfizer Recruiting
This report describes the first case of peritoneal carcinoma arising after RRSO in a Japanese patient with BRCA1 mutation, including a review of the literature on peritoneal carcinoma associated with BRCA1/2 mutation. PMID: 29094253 [PubMed - as supplied by publisher]